by Vandana Singh | Jan 15, 2026 | General
ImmunityBio, Inc. (NASDAQ:IBRX) shares are up on Thursday as the company is reporting continued execution and sales momentum, with a significant increase in preliminary net product revenue. IBRX Reports 700% Revenue Surge in 2025 ImmunityBio announced preliminary net...
by Vandana Singh | Jan 15, 2026 | General
The U.S. Food and Drug Administration on Thursday granted 510(k) clearance for Becton, Dickinson and Company’s (NYSE:BDX) new breast biopsy system. The FDA approved BD’s EnCor EnCompass Breast Biopsy and Tissue Removal System, which is expected to hit the market in...
by Vandana Singh | Jan 15, 2026 | General
Johnson & Johnson (NYSE:JNJ) shared topline results from the investigational Phase 3 MajesTEC-9 study of Tecvayli (teclistamab-cqyv) monotherapy for multiple myeloma, a type of blood cancer. The MajesTEC-9 study evaluates the efficacy and safety of Tecvayli versus...
by Surbhi Jain | Jan 15, 2026 | General
Oracle Corp’s (NYSE:ORCL) equity story still sounds familiar: AI infrastructure, hyperscale ambition, and a landmark partnership with OpenAI. But in the bond market, something has already snapped — and it’s happening far away from the stock ticker. Track...
by Vandana Singh | Jan 15, 2026 | General
OS Therapies Incorporated (NYSE:OSTX) shares are down on Thursday following the announcement of positive biomarker data from its Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma, a type of bone cancer. OST-HER2, the...
Recent Comments